Data Sheet 2_Early prostaglandin E1 treatment improves visual outcomes in central retinal artery occlusion: a retrospective study.xlsx

BackgroundCentral retinal artery occlusion (CRAO) is a vision-threatening emergency with no established effective treatment. Prostaglandin E1 (PGE1), known for its vasodilatory and cytoprotective properties, may offer therapeutic benefits for retinal ischemia.
MethodsIn this retrospective study, we compared visual outcomes between CRAO patients who received intravenous PGE1 within 24 hours of symptom onset (followed by oral administration) and those who received conventional therapy. PGE1 was administered intravenously for 5 days.
ResultsAt one month, the PGE1 group showed significantly better best-corrected visual acuity compared to the control group. Baseline structural retinal parameters, including maximal retinal thickness (MRT) and central retinal thickness (CRT), did not differ significantly between groups. In the PGE1 group, baseline MRT was negatively correlated with visual acuity at one month. Retinal arteriovenous diameters showed no significant change post-treatment. No adverse events were observed in either group.
ConclusionEarly administration of PGE1 may improve visual outcomes in CRAO. These findings support further investigation into PGE1 as a potential treatment for acute retinal ischemia.

背景：视网膜中央动脉阻塞（central retinal artery occlusion, CRAO）是一类威胁视力的急症，目前尚无公认的有效治疗方案。前列腺素E1（Prostaglandin E1, PGE1）具备血管舒张与细胞保护特性，或可为视网膜缺血带来治疗获益。
方法：本回顾性研究对比了症状发作24小时内接受静脉输注前列腺素E1（后续改为口服给药）的视网膜中央动脉阻塞患者与接受常规治疗患者的视力转归。前列腺素E1的静脉给药时长为5天。
结果：治疗1个月时，前列腺素E1组患者的最佳矫正视力显著优于对照组。两组的基线视网膜结构参数（包括最大视网膜厚度（maximal retinal thickness, MRT）与中心视网膜厚度（central retinal thickness, CRT））无显著差异。在前列腺素E1组中，基线最大视网膜厚度与治疗1个月时的视力呈负相关。治疗后视网膜动静脉直径无显著变化。两组均未观察到不良事件。
结论：早期应用前列腺素E1或可改善视网膜中央动脉阻塞患者的视力转归。本研究结果支持进一步探索前列腺素E1作为急性视网膜缺血的潜在治疗方案。